{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sodium+chloride+injection+%280.9%25%29&page=6",
    "query": {
      "intervention": "Sodium chloride injection (0.9%)",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 690,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sodium+chloride+injection+%280.9%25%29&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sodium+chloride+injection+%280.9%25%29&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T04:14:07.396Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02209272",
      "title": "Comparison of Bacteriostatic Saline to Buffered Lidocaine for Ultrasound Guided Hip Joint Injection Local Anesthesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hip Pain"
      ],
      "interventions": [
        {
          "name": "bacteriostatic saline",
          "type": "DRUG"
        },
        {
          "name": "buffered lidocaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 68,
      "start_date": "2014-08",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2019-04-11",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02209272"
    },
    {
      "nct_id": "NCT00774930",
      "title": "An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoid Syndrome"
      ],
      "interventions": [
        {
          "name": "Lanreotide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2009-05",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Stanford, California • West Hollywood, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774930"
    },
    {
      "nct_id": "NCT05189210",
      "title": "GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild to Moderate Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "GV1001 Placebo",
          "type": "DRUG"
        },
        {
          "name": "GV1001 0.56mg",
          "type": "DRUG"
        },
        {
          "name": "GV1001 1.12mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GemVax & Kael",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 199,
      "start_date": "2022-10-05",
      "completion_date": "2025-04-16",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 12,
      "location_summary": "Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Adventura",
          "state": "Florida"
        },
        {
          "city": "Greenacres City",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05189210"
    },
    {
      "nct_id": "NCT05731440",
      "title": "Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "18F-Fluselenamyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-11-18",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05731440"
    },
    {
      "nct_id": "NCT02411084",
      "title": "Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Begelomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conventional Second-line Treatment",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Adienne SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-02",
      "completion_date": "2017-07-31",
      "has_results": true,
      "last_update_posted_date": "2020-01-30",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02411084"
    },
    {
      "nct_id": "NCT02915263",
      "title": "The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Complications",
        "Diabetes Mellitus",
        "Diabetic Neuropathies"
      ],
      "interventions": [
        {
          "name": "IGIV-C",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 13,
      "start_date": "2017-09-11",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-07",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915263"
    },
    {
      "nct_id": "NCT06842134",
      "title": "A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parenteral Nutrition"
      ],
      "interventions": [
        {
          "name": "Numeta G16%E",
          "type": "DRUG"
        },
        {
          "name": "Sodium Glycerophosphate Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxter Healthcare Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2025-01-27",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06842134"
    },
    {
      "nct_id": "NCT02682498",
      "title": "Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Arthroplasty, Replacement, Knee"
      ],
      "interventions": [
        {
          "name": "(Bupivacaine Liposome Injectable Suspension)",
          "type": "DRUG"
        },
        {
          "name": "Standard Preparation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2013-10",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-07-07",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02682498"
    },
    {
      "nct_id": "NCT05648110",
      "title": "Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19, SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "AZD5156 (Parent study Sentinel Safety Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Parent study Sentinel Safety Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EVUSHELD™ (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD3152 (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD3152 (Sub-study)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 - EVUSHELD™ (Sub-study)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "12 Years to 130 Years"
      },
      "enrollment_count": 3882,
      "start_date": "2022-12-16",
      "completion_date": "2025-02-11",
      "has_results": true,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 130,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05648110"
    },
    {
      "nct_id": "NCT05515874",
      "title": "Predicting Stroke Risk in ICAD With Novel MRI",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intracranial Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Feraheme",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-09-01",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-12T04:14:07.396Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05515874"
    }
  ]
}